You are about to leave the Clinical Value website now.
The aim of this study was to investigate the efficacy of combined detection of 5 serological tumor markers including macrophage migration inhibitory factor (MIF) and abnormal prothrombin (PIVKA-II) in the early diagnosis of primary liver cancer.
Huan L…
Catch up on the highlights of APASL 2023 with this congress report, covering session on hepatitis B, hepatitis C, hepatocellular carcinoma, and fatty liver disease. …
A/Prof Simone Strasser recently published an independent commentary in the Australian Medical Research and Journal “Research Review”, covering at length topics such as non-alcoholic liver disease as an increasing risk factor, hepatocellular carcinoma surveillance including ultrasound as the current standard of care, the nature of patients who should undergo surveillance, serological biomarkers, and biopsy. Watch the interview with A/Prof Strasser on her thoughts about HCC in Australia….
This study aimed to assess the clinical utility of PIVKA-II in addition to AFP in patients with HCC.
Bhatti ABHH, Naz K, Abbas G, Khan NY, Zia HH, Ahmed IN…
